Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1

American Journal of Respiratory Cell and Molecular Biology

Volumn 33, Issue 5, 2005, Pages 490-499

  Sithanandam, Gunamani ^a   Smith, George T ^b   Fields, Janet R ^b   Anderson, Lucy M ^b  

^a SAIC FREDERICK INC   (United States)

^b NONE

Author keywords

Akt; EGFR; ErbB3; Gab1; Lung epithelial cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADAPTOR PROTEIN; CYCLIN D1; DOCKING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GAB1 PROTEIN; GLYCOGEN SYNTHASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOBLOTTING; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CYCLIN D1; ENZYME ACTIVATION; EPITHELIAL CELLS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; PHOSPHOPROTEINS; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMALIA; MURINAE;

EID: 27644431814     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2005-0049OC     Document Type: Article

References (50)

1. Smith GJ, Le Mesurier SM, De Montfort ML, Lykke AWJ. Development and characterization of type 2 pneumocyte-related cell lines from normal adult mouse lung. Pathology 1984;16:401-405.
2. Bentel JM, Lykke AWJ, Smith GJ. Cloned murine non-malignant, spontaneously transformed and chemical tumor-derived cell lines related to the type 2 pneumocyte. Cell Biol Int Rep 1989;13:729-738.
3. Malkinson AM, Dwyer-Nield LD, Rice PL, Dinsdale D. Mouse lung epithelial cell lines: tools for the study of differentiation and the neoplastic phenotype. Toxicology 1997;123:53-100.
4. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
6. Aida S, Tamai S, Sekiguchi S, Shimizu N. Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies. Respiration (Herrlisheim) 1994;61:161-166.
7. Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 1992;7:1273-1278.
8. Yi ES, Harclerode C, Gondo M, Stephenson M, Brown RW, Younes M, Cagle PT. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 1997;10:142-148.
9. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-962.
10. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-2385.
11. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987;55:513-516.
12. Rachwal WJ, Bongiorno PF, Orringer MB, Whyte RI, Ethier SP, Beer DG. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 1995;72:56-64.
13. Poller DN, Spendlove I, Baker C, Church R, Ellis IO, Plowman GD, Mayer RJ. Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. J Pathol 1992;168:275-280.
14. Lai WW, Chen FF, Wu MH, Chow NH, Su WC, Ma MC, Su PF, Chen H, Lin MY, Tseng YL. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg 2001;72:1868-1876.
15. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10:1813-1821.
16. Ram TG, Ethier SP. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ 1996;7:551-561.
17. Sithanandam G, Smith GT, Masuda A, Takahashi T, Anderson LM, Fornwald LW. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/ phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis 2003;24:1581-1592.
18. Sithanandam G, Fornwald LW, Fields J, Anderson LM. Inactivation of ErbB3 by siRNA promotes apoptosis and blocks growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 2005;24:1847-1859.
19. McDoniels-Silver AL, Herzog CR, Tyson FL, Malkinson AM, You M. Inactivation of both Rb and p53 pathways in mouse lung epithelial cell lines. Exp Lung Res 2001;27:297-318.
20. Liu Y, Rohrschneider LR. The gift of Gab. FEBS Lett 2002;515:1-7.
21. Gu H, Neel BG. The 'Gab' in signal transduction. Trends Cell Biol 2003;13:122-130.
22. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-3997.
23. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B, Fandrich F. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001;386:293-301.
24. 473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2003;12:660-664.
25. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167.
26. Mukohara T, Kudoh S, Matsuura K, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Inoue K, Wanibuchi H, et al. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res 2004;24:11-17.
27. Chess PR, Ryan RM, Finkelstein JN. Tyrosine kinase activity is necessary for growth factor-stimulated rabbit type II pneumocyte proliferation. Pediatr Res 1994;36:481-486.
28. Ryan RM, Mineo-Kuhn MM, Kramer CM, Finkelstein JN. Growth factors alter neonatal type II alveolar epithelial cell proliferation. Am J Physiol 1994;266:L17-L22.
29. Zeng Q, Qian Z, Su T, Sun Q, Jiang H. The effects of transforming growth factor alpha and beta1 on the proliferation of alveolar type II cells in vitro. Zhonghua Bing Li Xue Za Zhi 1999;28:432-435.
30. Rice PL, Porter SE, Koski KM, Ramakrishna G, Chen A, Schrump D, Kazlauskas A, Malkinson AM. Reduced receptor expression for platelet-derived growth factor and epidermal growth factor in dividing mouse lung epithelial cells. Mol Carcinog 1999;25:285-294.
31. Manning CB, Cummins AB, Jung MW, Berlanger I, Timblin CR, Palmer C, Taatjes DJ, Hemenway D, Vacek P, Mossman BT. A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res 2002;62:4169-4175.
32. White MK, Strayer DS. Survival signaling in type II pneumocytes activated by surfactant protein-A. Exp Cell Res 2002;280:270-279.
33. Portnoy J, Curran-Everett D, Mason RJ. Keratinocyte growth factor stimulates alveolar type II cell proliferation through the ERK and PI3Kinase pathways. Am J Respir Cell Mol Biol 2004;30:901-907.
34. Mamay CL, Schauer IE, Rice PL, McDoniels-Silvers A, Dwyer-Nield LD, You M, Sclafani RA, Malkinson AM. Cyclin D1 as a proliferative marker regulating retinoblastoma phosphorylation in mouse lung epithelial cells. Cancer Lett 2001;168:165-172.
35. Buckley S, Driscoll B, Anderson KD, Warburton D. Cell cycle in alveolar epithelial type II cells: integration of Matrigel and KGF. Am J Physiol 1997;273:L572-L580.
36. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor-or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004;64:2601-2609.
37. Settle M, Gordon MD, Nadella M, Dankort D, Muller W, Jacobs JR. Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model. Oncogene 2003;22:1916-1926.
38. Gillgrass A, Cardiff RD, Sharan N, Kannan S, Muller WJ. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB2-mediated mammary tumor progression. Oncogene 2003;22:9151-9155.
39. Yamasaki S, Nishida K, Yoshida Y, Itoh M, Hibi M, Hirano T. Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2. Oncogene 2003;22:1546-1556.
40. Gensler M, Buschbeck M, Ullrich A. Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1. J Biol Chem 2004;279:12110-12116.
41. Kameda H, Risinger JI, Han BB, Baek SJ, Barrett JC, Glasgow WC, Eling TE. Identification of epidermal growth factor receptor-Grb2-associated binder-1-SHP-2 complex formation and its functional loss during neoplastic cell progression. Cell Growth Differ 2001;12:307-318.
42. Kameda H, Risinger JI, Han BB, Baek SJ, Barrett JC, Abe T, Takeuchi T, Glasgow WC, Eling TE. Expression of Gab1 lacking the pleckstrin homology domain is associated with neoplastic progression. Mol Cell Biol 2001;21:6895-6905.
43. Holgado-Magruda M, Wong AJ. Role of the Grb2-associated binder 1/SHP-2 interaction in cell growth and transformation. Cancer Res 2004;64:2007-2015.
44. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Ape deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004;279:43261-43272.
45. Yu CF, Liu ZX, Cantley LG. ERK negatively regulates the epidermal growth factor-mediated interaction of Gabi and the phosphatidylinositol 3-kinase. J Biol Chem 2002;277:19382-19388.
46. Kapoor GS, Zhan Y, Johnson GR, O'Rourke DM. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol 2004;24:823-836.
47. Mattoon DR, Lamothe B, Lax I, Schlessinger J. The docking protein Gab 1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol 2004;2:24.
48. Stein-Gerlach M, Wallasch C, Ullrich A. SHP-2, SH2-containing protein tyrosine phosphatase-2. Int J Biochem Cell Biol 1998;30:559-566.
49. Qu C-K, Yu W-M, Azzarelli B, Cooper S, Broxmeyer HE, Feng G-S. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol 1998;18:6075-6082.
50. Qu C-K, Yu W-M, Azzarelli B, Feng G-S. Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Proc Natl Acad Sci USA 1999;96:8528-8533.